Dr. Michael T. Hemann, M.D., Ph.D. serves as the Eisen and Chang Career Development Associate Professor of Biology at the Massachusetts Institute of Technology ( MIT"). Dr. Hemann has expertise in modeling therapeutic resistance in order to identify new drug targets where inhibition can synergize with existing therapies. His laboratory uses RNAi to study the roles of cancer relevant genes in mediating sensitivity and resistance to chemotherapeutic agents. He focused on understanding the role of genetic instability on acquired and intrinsic drug resistance. Dr. Hemann has been a Member of Scientific Advisory Board of Therapeutics at MetaStat, Inc. since February 4, 2012.